Azithromycin fumarate crystal form and preparation method thereof

By recrystallization in different solvents and combining X-ray powder diffraction and infrared detection, the stable crystal form of azithromycin fumarate was determined, and a specific preparation method was used to solve the lack of crystal form information and stability in the prior art. The problem has improved the bioavailability of drugs and therapeutic efficacy.

CN119060109AInactive Publication Date: 2024-12-03DEZHOU DEYAO PHARMA

Patent Information

Application Number
CN202411545654.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-01
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art has failed to effectively grasp the crystal form information of azithromycin fumarate, which affects its therapeutic efficacy and production quality, and lacks a stable preparation method.

Method used

By recrystallization in different solvents, combined with X-ray powder diffraction and infrared detection, the stable crystal form of azithromycin fumarate was determined, and crystals with specific X-ray powder diffraction and infrared spectral characteristics were prepared, using organic Methods of reflux of solvent, low temperature static crystallization and drying treatment.

Benefits of technology

The successful preparation of azithromycin fumarate crystal forms with good stability improves the bioavailability and therapeutic efficacy of the drug, and provides more comprehensive scientific data to support its production and clinical application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060109A_ABST
    Figure CN119060109A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to an azithromycin fumarate crystal form and a preparation method thereof. The azithromycin fumarate crystal form is radiated by Cu-K alpha, and an X-ray powder diffraction pattern expressed by a 2 theta angle has diffraction peaks at the positions of 6.91 degrees + / -0.2 degrees, 8.38 degrees + / -0.2 degrees, 9.93 degrees + / -0.2 degrees, 11.42 degrees + / -0.2 degrees, 12.42 degrees + / -0.2 degrees, 14.64 degrees + / -0.2 degrees, 15.58 degrees + / -0.2 degrees, 17.57 degrees + / -0.2 degrees, 18.13 degrees + / -0.2 degrees, 18.94 degrees + / -0.2 degrees, 20.04 degrees + / -0.2 degrees, 21.08 degrees + / -0.2 degrees, 21.55 degrees + / -0.2 degrees, 23.02 degrees + / -0.2 degrees, 23.69 degrees + / -0.2 degrees, 29.41 degrees + / -0.2 degrees and 29.92 The azithromycin fumarate crystal form has good stability, the preparation process is simple and controllable, and the azithromycin fumarate crystal form is suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, relates to a method for preparing a crystal form of azithromycin fumarate, and specifically discloses a crystal form of azithromycin fumarate and a method for preparing the same. Background Art

[0002] The chemical name of azithromycin fumarate is 9-deoxy-9α-methyl-9α-erythromycin A fumarate. Azithromycin has a broad antibacterial spectrum and has strong antibacterial effects on mycoplasmas, chlamydia, anaerobic bacteria and other bacteria. It is widely used in the clinic for respiratory system, urogenital system, skin and soft tissue infections. Azithromycin fumarate [9-deoxy-9α-methyl-9α-erythromycin A fumarate] is the reaction product of fumaric acid and azithromycin. It is a fumarate that changes the water / oil partition coefficient of azithromycin, improves the ester solubility and water solubility of the drug, makes it easier to be absorbed by the small intestine, increases the concentration of azithromycin in the blood, and thus improves the therapeutic efficacy. Compared with azithromycin, azithromycin fumarate can dissolve in an alkaline environment, can effectively release the drug, and promote the absorption of azithromycin. Therefore, azithromycin fumarate has a higher bioavailability in the human body.

[0003] Although the preparation method of azithromycin salt is reported in the literature, the specific crystal form information is not disclosed. The crystal form of the raw material is an important factor affecting the efficacy of the drug. In order to better ensure the therapeutic efficacy of azithromycin fumarate, it is very necessary to study the crystal form of azithromycin fumarate, and it is also very important to master the method of preparing azithromycin fumarate with stable crystal form. Provide more comprehensive scientific data support for the production, quality and clinical efficacy of azithromycin fumarate. Summary of the invention

[0004] The inventors of the present invention investigated the recrystallization products of azithromycin fumarate obtained in different solvents, performed X-ray powder diffraction and infrared detection on the obtained recrystallization products, and found that under certain specific crystallization conditions, a azithromycin fumarate crystal form with good stability can be obtained.

[0005] A crystalline form of azithromycin fumarate, whose X-ray powder diffraction spectrum using Cu-Kα radiation is as follows: θThe diffraction peaks at the angles are: 6.91°±0.2°, 8.38°±0.2°, 9.93°±0.2°, 11.42°±0.2°, 12.42°±0.2°, 14.64°±0.2°, 15.58°±0.2°, 17.57°±0.2°, 18.13°±0.2°, 18.94°±0.2°, 20.04°±0.2°, 21.08°±0.2°, 21.55°±0.2°, 23.02°±0.2°, 23.69°±0.2°, 29.41°±0.2°, and 29.92°±0.2°.

[0006] In some preferred embodiments of the present invention, Cu-Kα radiation and X-ray powder diffraction spectra are as follows: θ The diffraction peaks at the following angles are: 6.91°±0.2°, 8.38°±0.2°, 9.93°±0.2°, 11.42°±0.2°, 12.42°±0.2°, 12.72°±0.2°, 14.04°±0.2°, 14.64°±0.2°, 15.58°±0.2°, 16.61°±0.2°, 17.57°±0.2°, 18.13°±0.2°, 18 .94°±0.2°, 20.04°±0.2°, 21.08°±0.2°, 21.55°±0.2°, 23.02°±0.2°, 23.69°±0.2°, 24.96°±0.2°, 26.03°±0.2°, 27.77°±0.2°, 28.54°±0.2°, 29.41°±0.2°, 29.92°±0.2°, and 31.54°±0.2°.

[0007] Furthermore, the X-ray powder diffraction pattern of the azithromycin fumarate crystal form using Cu-Kα radiation is as follows: Figure 1 shown.

[0008] The infrared spectrum of the azithromycin fumarate crystal form of the present invention has characteristic absorption peaks at one or more of the following absorption wavenumbers: 3410.2±5 cm -1 、2976.3±5 cm -1 、2939.0±5 cm -1 、2834.6±5 cm -1 、2711.6±5 cm -1 、1787.2±5 cm -1 、1723.9±5 cm -1 、1578.5±5 cm -1 、1468.6±5 cm -1 、1384.7±5 cm -1、1354.9±5 cm -1 、1284.4±5 cm -1 、1187.2±5 cm -1 、1123.8±5 cm -1 、1079.1±5 cm -1 、1060.4±5 cm -1 、1015.7±5 cm -1 、984.0±5 cm -1 、903.9±5 cm -1 、864.7±5 cm -1 、807.0±5 cm -1 、736.1±5 cm -1 、663.5±5 cm -1 、579.6±5 cm -1 、514.4±5 cm -1 、464.1±5 cm -1 .

[0009] In some preferred embodiments of the present invention, there is a characteristic absorption peak at the following absorption wave number: 3410.2±5 cm -1 、2976.3±5 cm -1 、2939.0±5 cm -1 、2834.6±5 cm -1 、2711.6±5 cm -1 、1787.2±5 cm -1 、1723.9±5 cm -1 、1578.5±5 cm -1 、1468.6±5 cm -1 、1384.7±5 cm -1 、1354.9±5 cm -1 、1284.4±5 cm -1 、1187.2±5 cm -1 、1123.8±5 cm -1 、1079.1±5 cm -1 、1060.4±5 cm -1 、1015.7±5 cm -1 、984.0±5 cm -1 、903.9±5 cm -1 、864.7±5 cm -1 、807.0±5 cm -1 、736.1±5cm -1 、663.5±5 cm-1 、579.6±5 cm -1 、514.4±5 cm -1 、464.1±5 cm -1 .

[0010] The present invention discloses a method for preparing a crystalline form of a compound azithromycin fumarate, comprising the following steps: (1) adding azithromycin fumarate to an organic solvent, heating to reflux, and filtering while hot to obtain a filtrate; (2) adding another solvent to the filtrate obtained in step (1), adding a small amount of seed crystals, and standing at low temperature for crystallization; (3) The filtrate after standing and crystallizing under low temperature conditions in step (2) is filtered by suction, and the filter cake is placed in a drying oven to dry.

[0011] Furthermore, the organic solvent is any one of methanol, ethanol, tetrahydrofuran and acetone; the ratio of methanol volume (ml) to azithromycin fumarate mass (g) is 7:8, the ratio of ethanol volume (ml) to azithromycin fumarate mass (g) is 7:1, the ratio of tetrahydrofuran volume (ml) to azithromycin fumarate mass (g) is 4:1, the ratio of acetone volume (ml) to azithromycin fumarate mass (g) is 44:1, and the reflux time is 30 min.

[0012] Furthermore, the volume ratio of isopropyl ether to methanol is 5:1, the volume ratio of acetonitrile to methanol is 10:1, and the volume ratio of ethyl acetate to methanol is 4:1; the volume ratio of isopropyl ether to ethanol is 8.6:1, the volume ratio of acetonitrile to ethanol is 2.1:1, and the volume ratio of ethyl acetate to ethanol is 2:1; the volume ratio of isopropyl ether to tetrahydrofuran is 3:1, the volume ratio of acetonitrile to tetrahydrofuran is 1.75:1, and the volume ratio of ethyl acetate to tetrahydrofuran is 4:1; the volume ratio of isopropyl ether to acetone is 1.5:1, the volume ratio of acetonitrile to acetone is 1.2:1, and the volume ratio of ethyl acetate to acetone is 1:1.

[0013] In the preparation method of the azithromycin fumarate crystal form, the low temperature condition in step (2) is -15°C to -10°C, and the standing time is 24 h.

[0014] The drying condition in step (3) of the preparation method of azithromycin fumarate crystal form is drying at 70° C. for 3 h. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] The specific embodiments of the present invention are described in conjunction with the following drawings.

[0016] Figure 1The invention discloses an X-ray powder diffraction pattern of the azithromycin fumarate crystal form.

[0017] Figure 2 It is the X-ray powder diffraction pattern of the azithromycin fumarate crystal form prepared by recrystallization in Examples 1 to 3 of the present invention.

[0018] Figure 3 It is the X-ray powder diffraction pattern of the azithromycin fumarate crystal form prepared by recrystallization in Examples 4 to 6 of the present invention.

[0019] Figure 4 It is the X-ray powder diffraction pattern of the azithromycin fumarate crystal form prepared by recrystallization in Examples 7 to 9 of the present invention.

[0020] Figure 5 It is the X-ray powder diffraction pattern of the azithromycin fumarate crystal form prepared by recrystallization in Example 10 to Example 12 of the present invention.

[0021] Figure 6 This is an infrared spectrum of the azithromycin fumarate crystal prepared by recrystallization in Example 2 of the present invention.

[0022] Figure 7 This is an infrared spectrum of the azithromycin fumarate crystal prepared by recrystallization in Example 4 of the present invention.

[0023] Figure 8 This is an infrared spectrum of the azithromycin fumarate crystal prepared by recrystallization in Example 5 of the present invention.

[0024] Fig. 9 This is an infrared spectrum of the azithromycin fumarate crystal prepared by recrystallization in Example 6 of the present invention.

[0025] Fig.10 This is an infrared spectrum of the azithromycin fumarate crystal prepared by recrystallization in Example 8 of the present invention.

[0026] Fig.11 This is an infrared spectrum of the azithromycin fumarate crystal prepared by recrystallization in Example 11 of the present invention. DETAILED DESCRIPTION

[0027] The present invention will be further described below in conjunction with examples, which are only used to illustrate the present invention so that those skilled in the art can more fully understand the present invention, but the examples themselves do not limit the present invention in any way.

[0028] The X-ray powder diffraction data of the azithromycin fumarate crystal form of the present invention is measured on a Bruker D8 ADVANCE X-ray powder diffractometer, and the measurement conditions are: X-ray: Cu target, Kα, Kα(Å):1.5418 X-ray tube setting: 40 kv, 40 mA Scanning range (°2θ): 5°-60° Scan speed (seconds / step): 0.2 The infrared spectroscopy data of the azithromycin fumarate crystal form of the present invention was measured on an Agilent infrared spectrometer under the following conditions: Scan times: 8 Wavelength range (cm-1): 4000-400 Apodization : Happ - Genzel Example 1 Preparation of Azithromycin Fumarate Crystalline Form Add 35 ml of methanol to a round-bottom flask, add 40 g of azithromycin fumarate to the methanol, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 175 ml of isopropyl ether, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C for 24 h, filter out crystals in the bottle, dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0029] Example 2 Preparation of Azithromycin Fumarate Crystalline Form Add 35 ml of methanol to a round-bottom flask, add 40 g of azithromycin fumarate to the methanol, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 350 ml of acetonitrile, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C for 24 h, filter out crystals in the bottle, dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0030] Example 3 Preparation of Azithromycin Fumarate Crystalline Form Add 35 ml of methanol to a round-bottom flask, add 40 g of azithromycin fumarate to the methanol, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 140 ml of ethyl acetate, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C and let stand for 24 h, crystals precipitate in the bottle, filter by suction, and dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0031] The azithromycin fumarate obtained by recrystallization with a single solvent in Examples 1 to 3 was subjected to X-ray powder diffraction detection. The X-ray powder diffraction pattern of the azithromycin fumarate crystal form obtained is as follows: Figure 2 As shown, both are in 2 θ The angles are 6.91°±0.2°, 8.38°±0.2°, 9.93°±0.2°, 11.42°±0.2°, 12.42°±0.2°, 12.72°±0.2°, 14.04°±0.2°, 14.64°±0.2°, 15.58°±0.2°, 16.61°±0.2°, 17.57°±0.2°, 18.13°±0.2°, 18.94°±0.2 Diffraction peaks appeared at 20.04°±0.2°, 21.08°±0.2°, 21.55°±0.2°, 23.02°±0.2°, 23.69°±0.2°, 24.96°±0.2°, 26.03°±0.2°, 27.77°±0.2°, 28.54°±0.2°, 29.41°±0.2°, 29.92°±0.2°, and 31.54°±0.2°.

[0032] Example 4 Preparation of Azithromycin Fumarate Crystalline Form Add 70 ml of ethanol to a round-bottom flask, add 10 g of azithromycin fumarate to the ethanol, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 600 ml of isopropyl ether, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C and let stand for 24 h, crystals precipitate in the bottle, filter by suction, and dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0033] Example 5 Preparation of Azithromycin Fumarate Crystalline Form Add 70 ml of ethanol to a round-bottom flask, add 10 g of azithromycin fumarate to the ethanol, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 150 ml of acetonitrile, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C for 24 h, filter out crystals in the bottle, dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0034] Example 6 Preparation of Azithromycin Fumarate Crystalline Form Add 70 ml of ethanol to a round-bottom flask, add 10 g of azithromycin fumarate to the ethanol, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 140 ml of ethyl acetate, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C for 24 h, filter out crystals in the bottle, dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0035] The azithromycin fumarate obtained by recrystallization with a single solvent in Examples 4 to 6 was subjected to X-ray powder diffraction detection. The X-ray powder diffraction pattern of the azithromycin fumarate crystal form obtained is as follows: Figure 3 As shown, both are in 2 θ The angles are 6.91°±0.2°, 8.38°±0.2°, 9.93°±0.2°, 11.42°±0.2°, 12.42°±0.2°, 12.72°±0.2°, 14.04°±0.2°, 14.64°±0.2°, 15.58°±0.2°, 16.61°±0.2°, 17.57°±0.2°, 18.13°±0.2°, 18.94°±0.2 Diffraction peaks appeared at 20.04°±0.2°, 21.08°±0.2°, 21.55°±0.2°, 23.02°±0.2°, 23.69°±0.2°, 24.96°±0.2°, 26.03°±0.2°, 27.77°±0.2°, 28.54°±0.2°, 29.41°±0.2°, 29.92°±0.2°, and 31.54°±0.2°.

[0036] Example 7 Preparation of Azithromycin Fumarate Crystalline Form Add 40 ml of tetrahydrofuran to a round-bottom flask, add 10 g of azithromycin fumarate to the tetrahydrofuran, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 120 ml of isopropyl ether, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C and let stand for 24 h, crystals precipitate in the bottle, filter by suction, and dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0037] Example 8 Preparation of Azithromycin Fumarate Crystalline Form Add 40 ml of tetrahydrofuran to a round-bottom flask, add 10 g of azithromycin fumarate to tetrahydrofuran, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 70 ml of acetonitrile, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C and let stand for 24 h, crystals precipitate in the bottle, filter by suction, and dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0038] Example 9 Preparation of Azithromycin Fumarate Crystalline Form Add 40 ml of tetrahydrofuran to a round-bottom flask, add 10 g of azithromycin fumarate to the tetrahydrofuran, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 160 ml of ethyl acetate, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C and let stand for 24 h, crystals precipitate in the bottle, filter by suction, and dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0039] The azithromycin fumarate obtained by recrystallization with a single solvent in Examples 7 to 9 was subjected to X-ray powder diffraction detection. The X-ray powder diffraction pattern of the azithromycin fumarate crystal form obtained is as follows: Figure 4 As shown, both are in 2 θ The angles are 6.91°±0.2°, 8.38°±0.2°, 9.93°±0.2°, 11.42°±0.2°, 12.42°±0.2°, 12.72°±0.2°, 14.04°±0.2°, 14.64°±0.2°, 15.58°±0.2°, 16.61°±0.2°, 17.57°±0.2°, 18.13°±0.2°, 18.94°±0.2 Diffraction peaks appeared at 20.04°±0.2°, 21.08°±0.2°, 21.55°±0.2°, 23.02°±0.2°, 23.69°±0.2°, 24.96°±0.2°, 26.03°±0.2°, 27.77°±0.2°, 28.54°±0.2°, 29.41°±0.2°, 29.92°±0.2°, and 31.54°±0.2°.

[0040] Example 10 Preparation of Azithromycin Fumarate Crystalline Form Add 220 ml of acetone to a round-bottom flask, add 5 g of azithromycin fumarate to the acetone, heat to reflux, reflux for 30 min, azithromycin fumarate is not completely dissolved, filter while hot, transfer the filtrate to a round-bottom flask, add 330 ml of isopropyl ether, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C and let stand for 24 h, crystals precipitate in the bottle, filter by suction, and dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0041] Example 11 Preparation of Azithromycin Fumarate Crystalline Form Add 220 ml of acetone to a round-bottom flask, add 5 g of azithromycin fumarate to the acetone, heat to reflux, reflux for 30 min, azithromycin fumarate is not completely dissolved, filter while hot, transfer the filtrate to a round-bottom flask, add 270 ml of acetonitrile, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C and let stand for 24 h, crystals precipitate in the bottle, filter by suction, and dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0042] Example 12 Preparation of Azithromycin Fumarate Crystalline Form Add 220 ml of acetone to a round-bottom flask, add 5 g of azithromycin fumarate to the acetone, heat to reflux, reflux for 30 min, filter while hot after the azithromycin fumarate is dissolved, transfer the filtrate to a round-bottom flask, add 220 ml of ethyl acetate, add a small amount of seed crystals, place in a low-temperature reaction bath at -10--15°C for 24 h, crystals precipitate in the bottle, filter by suction, and dry the filter cake in a 70°C drying oven for 3 h to obtain recrystallized azithromycin fumarate.

[0043] The azithromycin fumarate obtained by recrystallization with a single solvent in Example 10 to Example 12 was subjected to X-ray powder diffraction detection. The X-ray powder diffraction pattern of the azithromycin fumarate crystal form obtained is as follows: Figure 5 As shown, both are in 2 θ The angles are 6.91°±0.2°, 8.38°±0.2°, 9.93°±0.2°, 11.42°±0.2°, 12.42°±0.2°, 12.72°±0.2°, 14.04°±0.2°, 14.64°±0.2°, 15.58°±0.2°, 16.61°±0.2°, 17.57°±0.2°, 18.13°±0.2°, 18.94°±0.2 Diffraction peaks appeared at 20.04°±0.2°, 21.08°±0.2°, 21.55°±0.2°, 23.02°±0.2°, 23.69°±0.2°, 24.96°±0.2°, 26.03°±0.2°, 27.77°±0.2°, 28.54°±0.2°, 29.41°±0.2°, 29.92°±0.2°, and 31.54°±0.2°.

[0044] The infrared spectrometer was used to detect Example 2, Example 4, Example 5, Example 6, Example 8, and Example 11, and the infrared spectra of the obtained azithromycin fumarate crystal form are as follows: Figure 6 —11 shows that the absorption wave number is 3410.2±5 cm -1 、2976.3±5 cm -1 、2939.0±5 cm-1 、2834.6±5 cm -1 、2711.6±5 cm -1 、1787.2±5 cm -1 、1723.9±5 cm -1 、1578.5±5 cm -1 、1468.6±5 cm -1 、1384.7±5 cm -1 、1354.9±5 cm -1 、1284.4±5 cm -1 、1187.2±5 cm -1 、1123.8±5 cm -1 、1079.1±5 cm -1 、1060.4±5 cm -1 、1015.7±5 cm -1 、984.0±5 cm -1 、903.9±5 cm -1 、864.7±5 cm -1 、807.0±5 cm -1 、736.1±5cm -1 、663.5±5 cm -1 、579.6±5 cm -1 、514.4±5 cm -1 、464.1±5 cm -1 An absorption peak appears.

[0045] Finally, it should be noted that the above examples are only used to further illustrate the present invention, rather than to limit the scope of protection of the present invention. Some non-essential improvements and adjustments made by technicians in this field based on the above content of the present invention all fall within the scope of protection of the present invention.

Claims

1. A crystalline form of azithromycin fumarate, characterized in that: Its X-ray powder diffraction spectrum using Cu-Kα radiation is as follows: θ The diffraction peaks at the angles are: 6.91°±0.2°, 8.38°±0.2°, 9.93°±0.2°, 11.42°±0.2°, 12.42°±0.2°, 14.64°±0.2°, 15.58°±0.2°, 17.57°±0.2°, 18.13°±0.2°, 18.94°±0.2°, 20.04°±0.2°, 21.08°±0.2°, 21.55°±0.2°, 23.02°±0.2°, 23.69°±0.2°, 29.41°±0.2°, and 29.92°±0.2°.

2. The azithromycin fumarate crystal form according to claim 1, characterized in that: Its X-ray powder diffraction spectrum using Cu-Kα radiation is as follows: θ The diffraction peaks at the following angles are: 6.91°±0.2°, 8.38°±0.2°, 9.93°±0.2°, 11.42°±0.2°, 12.42°±0.2°, 12.72°±0.2°, 14.04°±0.2°, 14.64°±0.2°, 15.58°±0.2°, 16.61°±0.2°, 17.57°±0.2°, 18.13°±0.2°, 18 .94°±0.2°, 20.04°±0.2°, 21.08°±0.2°, 21.55°±0.2°, 23.02°±0.2°, 23.69°±0.2°, 24.96°±0.2°, 26.03°±0.2°, 27.77°±0.2°, 28.54°±0.2°, 29.41°±0.2°, 29.92°±0.2°, and 31.54°±0.2°.

3. A crystalline form of azithromycin fumarate according to any one of claims 1 to 2, characterized in that: Its infrared spectrum has characteristic absorption peaks at one or more of the following absorption wavenumbers: 3410.2±5 cm -1 、2976.3±5 cm -1 、2939.0±5 cm -1 、2834.6±5 cm -1 、2711.6±5 cm -1 、1787.2±5 cm -1 、1723.9±5 cm -1 、1578.5±5 cm -1 、1468.6±5 cm -1 、1384.7±5 cm -1 、1354.9±5 cm -1 、1284.4±5 cm -1 、1187.2±5 cm -1 、1123.8±5 cm -1 、1079.1±5 cm -1 、1060.4±5 cm -1 、1015.7±5 cm -1 、984.0±5 cm -1 、903.9±5 cm -1 、864.7±5 cm -1 、807.0±5 cm -1 、736.1±5 cm -1 、663.5±5 cm -1 、579.6±5 cm -1 、514.4±5 cm -1 、464.1±5 cm -1 .

4. A crystalline form of azithromycin fumarate according to any one of claims 1 to 2, characterized in that: Its infrared spectrum has characteristic absorption peaks at the following absorption wavenumbers: 3410.2±5 cm -1 、2976.3±5 cm -1 、2939.0±5 cm -1 、2834.6±5 cm -1 、2711.6±5 cm -1 、1787.2±5 cm -1 、1723.9±5 cm -1 、1578.5±5 cm -1 、1468.6±5 cm -1 、1384.7±5 cm -1 、1354.9±5 cm -1 、1284.4±5 cm -1 、1187.2±5 cm -1 、1123.8±5 cm -1 、1079.1±5 cm -1 、1060.4±5 cm -1 、1015.7±5 cm -1 、984.0±5 cm -1 、903.9±5 cm -1 、864.7±5 cm -1 、807.0±5 cm -1 、736.1±5 cm -1 、663.5±5 cm -1 、579.6±5 cm -1 、514.4±5 cm -1 、464.1±5 cm -1 .

5. A method for preparing a crystalline form of azithromycin fumarate according to claim 1, characterized in that: The preparation method comprises the following steps: (1) adding azithromycin fumarate to an organic solvent, heating to reflux, and filtering while hot to obtain a filtrate; (2) adding another solvent to the filtrate obtained in step (1), adding a small amount of seed crystals, and standing at low temperature for crystallization; (3) The filtrate after standing and crystallizing under low temperature conditions in step (2) is filtered by suction, and the filter cake is placed in a drying oven to dry.

6. The method for preparing a crystalline form of azithromycin fumarate according to claim 5, characterized in that: The organic solvent is any one of methanol, ethanol, tetrahydrofuran and acetone; the other solvent is any one of isopropyl ether, acetonitrile and ethyl acetate.

7. The method for preparing a crystalline form of azithromycin fumarate according to claim 6, characterized in that: The ratio of the volume amount (ml) of methanol to the mass (g) of azithromycin fumarate is 7:8, the ratio of the volume amount (ml) of ethanol to the mass (g) of azithromycin fumarate is 7:1, the ratio of the volume amount (ml) of tetrahydrofuran to the mass (g) of azithromycin fumarate is 4:1, the ratio of the volume amount (ml) of acetone to the mass (g) of azithromycin fumarate is 5:1, and the reflux time is 30 min.

8. The method for preparing a crystalline form of azithromycin fumarate according to claim 6, characterized in that: The volume ratio of isopropyl ether to methanol is 5:1, the volume ratio of acetonitrile to methanol is 10:1, and the volume ratio of ethyl acetate to methanol is 4:1; the volume ratio of isopropyl ether to ethanol is 8.6:1, the volume ratio of acetonitrile to ethanol is 2.1:1, and the volume ratio of ethyl acetate to ethanol is 2:1; the volume ratio of isopropyl ether to tetrahydrofuran is 3:1, the volume ratio of acetonitrile to tetrahydrofuran is 1.75:1, and the volume ratio of ethyl acetate to tetrahydrofuran is 4:1; the volume ratio of isopropyl ether to acetone is 1.5:1, the volume ratio of acetonitrile to acetone is 1.2:1, and the volume ratio of ethyl acetate to acetone is 1:

1.

9. The method for preparing a crystalline form of azithromycin fumarate according to claim 5, characterized in that: In step (2), the low temperature condition is -15°C to -10°C, and the standing time is 24 h.

10. The method for preparing a crystalline form of azithromycin fumarate according to claim 5, characterized in that: The drying step in step (3) is performed at 70° C. for 3 h.

Citation Information

Patent Citations

  • Crystal forms of azithromycin

    CA2536501A1

  • Hydrate of azithromycin, and preparation and use thereof

    CN101412740A

  • Soluble salt of azithromycin and its preparation process

    CN1789273A

Cited By

  • Novel low-hygroscopicity azithromycin fumarate crystal form B and preparation method thereof

    CN120842293A